Welcome

Welcome

Founded in Sweden in 2007, Redoxis focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). Redoxis’ core competencies in in Vivo and in Vitro models of autoimmune inflammation are the basis for our CRO services in preclinical drug validation. Redoxis’ experienced research team have specialized competencies in immunology, animal models and target validation. Our efficient...

read more

Research area

Research area

Redoxis holds a portfolio of research projects for the treatment of chronic inflammatory and autoimmune diseases, linked together by a large unmet medical need and large patient populations or high-value niche therapy areas. Redoxis research actively targets pathways identified by forward genetics with the aim of identifying and developing novel small molecule therapies.   Redoxis targets major inflammatory diseases such as Rheumatoid Arthritis (RA), Multiple Sclerosis (MS) and Inflammatory Bowel Disease (IBD).  In some instances, we...

read more

Mission

Mission

Redoxis have a dedicated research team with long experience and specialist competence in immunology, animal models and drug target validation. By combining close academic collaborations with a cost-efficient, structural and flexible target validation process we have specialized in efficient validation of novel drug- targets for continued preclinical validation and candidate drug selection. During lead development phase of novel drug candidates Redoxis actively searches for partnership with venture capitalists or pharma industry for preclinical...

read more

Laboratory Services

Laboratory Services

We provide research services in the area of discovery and early preclinical development. Our main expertise are In Vivo and In Vitro models for inflammatory, autoimmune conditions like Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS). The advantage of having Redoxis as partner in early drug development is our flexibility, devotion and competence. Our partner projects are the main priority concerning communication, reports and performance and we provide:   -Personnel with many years experience of study design, assaying and...

read more
Bookmark and Share